---
title: Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene
  Ciloleucel Across Race and Ethnicity
date: '2024-04-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38635762/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240419180722&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric
  antigen receptor (CAR) T-cell therapy approved for treatment of relapsed/refractory
  (R/R) large B-cell lymphoma (LBCL). Despite extensive data supporting the use of
  axi-cel in patients with LBCL, outcomes stratified by race and ethnicity groups
  are limited. Here, we report clinical outcomes with axi-cel in patients with R/R
  LBCL by race and ethnicity in both real-world and clinical trial settings. In the
  real-world ...
disable_comments: true
---
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Despite extensive data supporting the use of axi-cel in patients with LBCL, outcomes stratified by race and ethnicity groups are limited. Here, we report clinical outcomes with axi-cel in patients with R/R LBCL by race and ethnicity in both real-world and clinical trial settings. In the real-world ...